Orthovita to Market Medafor's MPH® Hemostatic Technology Under the Name VITASURE™.
MINNEAPOLIS, April 27, 2008 - Medafor is pleased to announce that it has signed a non-exclusive agreement with Orthovita, Inc., Philadelphia, Penna., to distribute Medafor's patented MPH® polysaccharide hemostatic technology under the private label VITASURE™.

CryoLife Signs Exclusive Agreement to Distribute Medafor's MPH® Technology
MINNEAPOLIS, April 25, 2008 - Medafor is pleased to announce that it has signed an exclusive agreement with CryoLife, Inc., Atlanta, Ga., to distribute Medafor's patented MPH® polysaccharide hemostatic technology under the private label Hemostase MPH beginning May 1, 2008.

FDA OKs Arista™AH for U.S. Operating Rooms
Medafor's Arista™AH Absorbable Surgical Hemostat recently received FDA PMA for surgical markets within the U.S. Arista™AH has been distributed internationally since 2002 and has compiled a remarkable record of surgical successes around the world.

Chicago, Illinois
112th Annual Meeting and OTO Expo, American Academy of Otolaryngology
September 21-24, 2008

San Francisco, California
94th Annual Clinical Congress, American College of Surgeons
October 12-16, 2008

HOME | ABOUT MEDAFOR | PRODUCTS | TECHNOLOGY | RESEARCH | MEDIA CENTER | CONTACT US

Medafor, Inc., was founded in 1999 to develop and market applications for its patented MPH® (Microporous Polysaccharide Hemospheres Technology). Statements presented on this page have not been evaluated by the U.S. FDA. See respective Instructions for Use for product applications and indications. Site content and images Copyright 2007 Medafor, Inc. All Rights Reserved. No part of this site may be copied, republished, excerpted or transferred to other media without the express written consent of Medafor, Inc. Arista™AH, MPH®, Medafor®, MPatcH®, FlexiTip™ are trademarks of Medafor, Inc. Other trademarks mentioned are the property of their respective companies. For information, contact Medafor at 1-763-571-6300.